4-year follow-up of a RCT | Pembrolizumab with vs. without chemotherapy in recurrent or metastatic head and neck SCC.

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study – Journal of Clinical Oncology

Original Study: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)